anipharmaceuticals.com (ANIP): Net earnings per share growth forecast for next year
ANI Pharmaceuticals combines its own production capacities with GMP-standard contract manufacturing services. Stable demand for niche prescriptions ensures a steady cash flow. The trajectory of forward EPS estimate revisions reflects market expectations, where the value 7.60 serves as the baseline indicator. Efficient medication distribution through pharmacy chains guarantees therapy accessibility and optimizes patient costs.
ANIP (ANI Pharma): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Total Debt to Capital ANI Pharmaceuticals|ANIP - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio ANI Pharma|ANIP - Aggregate Debt Obligations|Debt to Book Capitalization Ratio ANI Pharmaceuticals, Inc.|ANIP - Long-Term Liabilities|Company Short-Term Debts ANI Pharmaceuticals|Quick Ratio anipharmaceuticals.com
- earnings and valuation multiples information:
ANIP - Net Profit|Expected Profit ANI Pharmaceuticals|ANIP - Company Value to Net Income|Future Price to Earnings ANI Pharmaceuticals Inc|ANIP - Price/Earnings to Growth Multiple|EV/EBITDA Multiple ANI Pharmaceuticals, Inc.|ANIP - Operating profit EBITDA|Net earnings per share (EPS TTM) ANI Pharmaceuticals|ANIP - Net earnings per share for the last 12 months|Quarterly EPS earnings growth anipharmaceuticals.com|ANIP - Earnings per share growth rate in current year|Expected earnings per share growth for next year ANI Pharmaceuticals
- revenue and sales proceeds data:
Fundamental company valuation:ANIP, ANI Pharma
This indicator aggregates analyst consensus earnings per share (EPS) forecasts, reflecting the market's valuation of future profitability through the lens of expected cash flows. For ANI Pharmaceuticals (ANIP), which is growing through the acquisition of generic rights, this projected net income trend serves as a benchmark for the efficiency of new asset integration and determines the acceptable risk premium in the share price.
Who ANI Pharmaceuticals competes with
Net earnings per share growth forecast for next year Haleon plc|Expected net earnings per share growth next year kenvue.com KVUE|Net earnings per share growth forecast for next year Verona Pharma (VRNA)|MENS (Jyong Biotech Limited) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Ligand Pharma LGND|Earnings growth forecast for next year Amneal Corp AMRX|Perrigo Company PLC - Earnings growth forecast for next year|ALVO: Net earnings per share growth forecast for next year|liquidia.com (LQDA) - Net earnings per share growth forecast for next year|GLPG (Galapagos) - Net earnings per share growth forecast for next year|Net earnings per share growth forecast for next year MannKind Corporation|AMPH: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Pacira BioSciences (PCRX)|SPRY: Net earnings per share change forecast for next year|Theravance Biopharma, Inc. - Expected earnings per share growth for next year|Projected earnings per share increase next year AQST (Aquestive Therapeutics, Inc.)|SCPH - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year tectonictx.com TECX|TNXP: Earnings growth forecast for next year|Projected earnings per share growth rate for next year SXTC|Expected earnings per share growth for next year EPRX|BioHarvest (BHST) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year EXOZ|Earnings growth forecast for next year Oramed (ORMP)|Entera Bio Ltd. - Expected earnings per share growth for next year|ipatherapeutics.com (HYFT) - Expected net earnings per share growth next year|ABVC - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year CPIX|QNTM: Earnings growth forecast for next year|FGEN - Consensus forecast of earnings per share growth for next year|TELO (Telomir Pharmaceuticals Corp) - Earnings growth forecast for next year|RANI (Rani Therapeutics) - Projected earnings per share increase next year|Net earnings per share growth forecast for next year Synergy CHC Corp. (SNYR)|RLYB (Rallybio) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year lexariabioscience.com LEXX|Earnings growth forecast for next year Pulmatrix Corporation PULM|PTHL - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Aptorum Group Ltd APM|LYRA (Lyra Therapeutics) - Expected earnings per share growth for next year|IBO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year TNF Pharmaceuticals, Inc.|Expected earnings per share growth for next year cbdMD, Inc. (YCBD)|Net earnings per share growth forecast for next year PainReform Limited (PRFX)|Expected earnings per share growth for next year Altamira Therapeutics Ltd CYTO|Earnings growth forecast for next year LIPO (lipella.com)|Expected earnings per share trend next year OPTN|PIRS - Net earnings per share growth forecast for next year|Procaps Group Corp (PROC) - Expected earnings per share growth for next year|Petros (PTPI) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year QLI (Qilian International)|Expected earnings per share growth for next year SLRN|TFF Pharmaceuticals, Inc. - Net earnings per share change forecast for next year
